newsfilter
← Earnings
Earnings Releases·

UroGen Pharma Ltd. — Third Quarter 2026 Earnings Summary

UroGen Pharma reported $68.0 million in ZUSDURI revenue for the third quarter of 2026, marking a 35% increase from the previous quarter. The company received FDA acceptance for its New Drug Application for UGN-103, with a PDUFA goal date set for June 14, 2027, and announced the first patient dosed in the UGN-501 Phase 1 trial. Total revenue for the quarter reached $89.0 million, driven by commercial growth, while the company reported a net loss of $1.5 million. Additionally, UroGen updated its full-year 2026 JELMYTO revenue guidance to approximately $90 million and confirmed a strategic collaboration with IntraGel Therapeutics.

Company
UROGEN PHARMA LTD
Sector
Healthcare
Industry
Biotechnology